We have studied the application of a synergistic formulation of IFNs to explore, as primary objective, the safety and the clinical response with IFN combination treatment in advanced, recurrent and non-responder to previous treatments BCC and SCSC without any other therapeutic option. Here, IFNA1 is linked to skin basal cell carcinoma.